Cargando…

Evaluation of serum interleukin‐1 receptor antagonist levels in major depressive disorder: A case‐control study

BACKGROUND AND AIMS: Major depressive disorder (MDD) is characterized by the occurrence of one or more depressive episodes lasting a minimum of 2 weeks and is marked by a persistently low mood and a lack of enjoyment in daily activities. The diagnosis of MDD is not possible by a well‐established lab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nahar, Zabun, Monisha, Shahrin Tasnim, Qusar, MMA Shalahuddin, Islam, Md. Rabiul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050969/ https://www.ncbi.nlm.nih.gov/pubmed/37008817 http://dx.doi.org/10.1002/hsr2.1175

Ejemplares similares

Higher serum interleukin‐12 levels are associated with the pathophysiology of major depressive disorder: A case‐control study results
por: Nahar, Zabun, et al.
Publicado: (2022)

Increased serum resistin but not G-CSF levels are associated in the pathophysiology of major depressive disorder: Findings from a case-control study
por: Rahman, Smaranika, et al.
Publicado: (2022)

Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study
por: Akter, Sarmin, et al.
Publicado: (2023)

Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder
por: Anjum, Sadia, et al.
Publicado: (2020)

Higher serum nerve growth factor levels are associated with major depressive disorder pathophysiology: a case–control study
por: Salsabil, Lubaba, et al.
Publicado: (2023)

Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients
por: Nishuty, Nuruna Lovely, et al.
Publicado: (2019)

Community‐based decentralized mental health services are essential to prevent the epidemic turn of post‐Covid mental disorders in Bangladesh: A call to action
por: Islam, Md. Rabiul, et al.
Publicado: (2022)

Altered serum adiponectin and interleukin-8 levels are associated in the pathophysiology of major depressive disorder: A case-control study
por: Islam, Salsabil, et al.
Publicado: (2022)

Association of reduced serum EGF and leptin levels with the pathophysiology of major depressive disorder: A case-control study
por: Sohan, Md., et al.
Publicado: (2023)

Alterations of serum macro-minerals and trace elements are associated with major depressive disorder: a case-control study
por: Islam, Md Rabiul, et al.
Publicado: (2018)

Altered serum TNF-α and MCP-4 levels are associated with the pathophysiology of major depressive disorder: A case-control study results
por: Nayem, Jannatul, et al.
Publicado: (2023)

Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study
por: Islam, Md Rabiul, et al.
Publicado: (2018)

Association of granulocyte macrophage colony-stimulating factor and interleukin-17 levels with obsessive–compulsive disorder: a case–control study findings
por: Sarker, Rapty, et al.
Publicado: (2023)

Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder
por: Islam, Md. Rabiul, et al.
Publicado: (2020)

Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy
por: Emon, Md. Prova Zaman, et al.
Publicado: (2020)

Unnecessary Cesarean Section Delivery Causes Risk to Both Mother and Baby: A Commentary on Pregnancy Complications and Women’s Health
por: Nahar, Zabun, et al.
Publicado: (2022)

Altered serum elements, antioxidants, MDA, and immunoglobulins are associated with an increased risk of seborrheic dermatitis
por: Jahan, Ishrat, et al.
Publicado: (2021)

Serum interferon-gamma level is associated with drug-naïve major depressive disorder
por: Daria, Sohel, et al.
Publicado: (2020)

Prevalence and associated factors for elevated fear and depressive symptoms among the private service holders in Bangladesh during the Covid‐19 pandemic: A cross‐sectional study
por: Islam, Md. Rabiul, et al.
Publicado: (2022)

Evaluation of Serum Lysophosphatidic Acid and Lysophosphatidylcholine Levels in Major Depressive Disorder Patients
por: Riya, Sumaia, et al.
Publicado: (2020)

Association of ORAI1 Genetic Polymorphism with Serum Calcium and Phosphorus Levels in Non-dialysis Chronic Kidney Disease Patients: A Case-control Study
por: Jahan, Ishrat, et al.
Publicado: (2019)

Elevated Serum IL-2 Levels are Associated With Major Depressive Disorder: A Case-Control Study
por: Suhee, Farhana Islam, et al.
Publicado: (2023)

Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention
por: Islam, Md Rabiul, et al.
Publicado: (2021)

Evaluation of Serum Glial Cell Line-derived Neurotrophic Factor in Bangladeshi Major Depressive Disorder Patients
por: Das, Rajesh, et al.
Publicado: (2019)

Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic
por: Rahman, Smaranika, et al.
Publicado: (2022)

Major Depressive Disorder and Kappa Opioid Receptor Antagonists
por: Li, Wei, et al.
Publicado: (2016)

Prevalence and associated risk factors for mental health problems among female university students during COVID-19 pandemic: A cross-sectional study findings from Dhaka, Bangladesh
por: Nahar, Zabun, et al.
Publicado: (2022)

Corrigendum to “Prevalence and associated risk factors for mental health problems among female university students during COVID-19 pandemic: A cross-sectional study findings from Dhaka, Bangladesh” [Heliyon 8 (10) (October 2022) Article e10890]
por: Nahar, Zabun, et al.
Publicado: (2023)

Problematic internet use and depressive symptoms among the school‐going adolescents in Bangladesh during the COVID‐19 pandemic: A cross‐sectional study findings
por: Islam, Md. Rabiul, et al.
Publicado: (2022)

Internet addiction and loneliness among school-going adolescents in Bangladesh in the context of the COVID-19 pandemic: Findings from a cross-sectional study
por: Islam, Md Rabiul, et al.
Publicado: (2023)

A dataset on the prevalence and associated risk factors for mental health problems among female university students in Bangladesh
por: Nahar, Zabun, et al.
Publicado: (2023)

Association analysis between variants of the interleukin-1β and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression
por: Tadić, André, et al.
Publicado: (2008)

Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis
por: Islam, Md Rabiul, et al.
Publicado: (2023)

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment‐resistant major depressive disorder
por: Yamasaki, Katsuhiko, et al.
Publicado: (2020)

Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis
por: Bao, Jun, et al.
Publicado: (2014)

Serum proteomic profiling of major depressive disorder
por: Bot, M, et al.
Publicado: (2015)

Physiologic role of interleukin-1 receptor antagonist
por: Arend, William P, et al.
Publicado: (2000)

Interleukin Expression after Injury and the Effects of Interleukin-1 Receptor Antagonist
por: Chamberlain, Connie S., et al.
Publicado: (2013)

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017)

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse
por: Bjrök, P., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_f2mlflrg5lnab1gp1va73s4s38